SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-563667
Filing Date
2016-04-28
Accepted
2016-04-28 16:05:41
Documents
56
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d344249d10q.htm 10-Q 369433
2 EX-31.1 d344249dex311.htm EX-31.1 8871
3 EX-31.2 d344249dex312.htm EX-31.2 8877
4 EX-32.1 d344249dex321.htm EX-32.1 3483
5 EX-32.2 d344249dex322.htm EX-32.2 3494
  Complete submission text file 0001193125-16-563667.txt   3342475

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT kerx-20160331.xml EX-101.INS 561695
7 XBRL TAXONOMY EXTENSION SCHEMA kerx-20160331.xsd EX-101.SCH 38083
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kerx-20160331_cal.xml EX-101.CAL 52232
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kerx-20160331_def.xml EX-101.DEF 255945
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE kerx-20160331_lab.xml EX-101.LAB 364377
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kerx-20160331_pre.xml EX-101.PRE 299258
Mailing Address
Business Address 750 LEXINGTON AVENUE . NEW YORK NY 10022 212-531-5965
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

IRS No.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30929 | Film No.: 161600027
SIC: 2834 Pharmaceutical Preparations